**Staten Serum Institute Summary**

Statement of problem: Staten Serum institute is developing new molecular testing paradymines for testing a broad range of non culturable bacterial pathogens that are present in both urine and swab specimens from male and female STD patients.

The basis for this approach is the NIH human microbiome study and the increased incidence and morbidity of STD related symptoms in female patient’s patient samples being referred to researchers at the Staten’s Serum institute.

1. Sierra was contacted in late 2008 by DR Jorgen Skov Jensen Md. PhD. about validating the urine preservative for bacterial urine applications. I provided Dr. Jensen with research evaluation material and we had a working collaboration throughout the study and validation process.
2. In May 2009 Dr. Jensen notified me that the chemistry had performed very well and that he was going to standardize the collection of urine samples for use in his research studies.
3. In June of 2009 Dr. Jensen asked if we had chemistry for use with swab specimens that would stabilize a group of non culturable STD pathogens that he could quantitate the RNA of the group using rtPCR and at the same time would not allow any growth of the target bacterial pathogens of interest. His point is that he had not been able to essentially freeze populations for using any existing technology.
4. I provided Dr. Jensen with our multiplex chemistry and while skeptical he agreed to do an in depth study based on the NIH microbiome protocol being utilized by the research group at LSU using our multiplex chemistry.
5. The methodology used rtPCR and RFLP the two agreed gold standards for quantifying bacterial RNA in target populations.
6. I was notified by Dr. Jensen in early 2010 that he had completed his validation studies and that the Multiplex formulation had worked extremely well and that he would be utilizing our chemistry for all his STD swab samples.
7. Staten’s Serum institute is now ordering large volumes of both the urine and multiplex Genelock products for use by Dr. Jensen’s laboratory.
8. At the AACC meeting in July Mark and I made a presentation to the marketing manager for Staten’s Serum Institute about the possibility of marketing the Genelock products in Europe. Mark has the details of that conversation.
9. August 2010 I asked Dr. Jensen if he would recommend that Staten’s Serum institute market the Genelock products based on his research and the excellent results he had. He agreed to endorse Genelock and recommend that Staten’s market the technology.
10. Mark was to forward Dr. Jensen’s response to the marketing person and follow up with her.